Rett Syndrome

Molecular Mechanism

• MECP2 mutation and loss of MeCP2 protein function: MECP2 encodes methyl-CpG-binding protein 2, a transcriptional regulator that binds methylated DNA and recruits corepressor complexes. Loss-of-function mutations result in reduced or absent MeCP2 protein, leading to dysregulation of gene expression
• Epigenetic dysregulation: MeCP2 normally silences genes through histone deacetylase recruitment; mutations impair transcriptional repression of both activating and silencing targets, causing imbalance in neuronal gene expression
• Neurotrophic factor dysfunction: Reduced brain-derived neurotrophic factor (BDNF) and abnormal nerve growth factor (NGF) signaling impair synaptic plasticity and neuronal survival
• Mitochondrial dysfunction: Impaired energy metabolism due to altered expression of genes regulating oxidative phosphorylation and ATP production
• Excitatory-inhibitory imbalance: Abnormal GABAergic and glutamatergic signaling due to dysregulation of neurotransmitter receptor genes and transporters
• Synaptic abnormalities: Reduced dendritic spine density, impaired synaptosomal function, and abnormal neurotransmitter release mechanisms
• Cellular consequences: Neurons form normally initially but undergo progressive dysfunction and degeneration after 6-18 months, with particular vulnerability in cortical and basal ganglia neurons

• MECP2 mutations: ~99% of classic Rett syndrome cases carry loss-of-function mutations in MECP2; >800 different mutations identified including point mutations, frameshifts, and large deletions; mutations typically occur de novo (sporadic inheritance in 90% of cases)
• X-linked inheritance pattern: Affected heterozygous females; hemizygous males typically lethal in utero or fatal in early infancy (male neonatal encephalopathy); rare surviving males have atypical phenotypes or somatic mosaicism
• Alternative genes in atypical forms: Mutations in CDKL5 (cyclin-dependent kinase-like 5) cause early infantile epileptic encephalopathy phenotype mimicking Rett; PCDH19 and FOXG1 mutations cause variant presentations
• X-inactivation effects: Random lyonization of X chromosome in heterozygous females results in variable clinical severity and symptom expression
• No established preventable risk factors: No maternal or environmental factors identified as modifiable risk factors; advanced paternal age may slightly increase de novo mutation risk

Stage I (Early Infantile Stage; 6-18 months)

• Apparently normal development with normal head circumference at birth
• Subtle developmental deceleration not always apparent to parents
• Possible early hypotonia or feeding difficulties
• Gradual decrease in purposeful hand use
• Loss of social engagement (eye contact deterioration)
• Short attention span; decreasing interest in environment

Stage II (Rapid Destructive Stage; 1-4 years)—Most Dramatic

• Rapid loss of purposeful hand skills (hallmark feature)—bilateral, symmetrical loss of fine motor control with regression from grasping to loss of manipulative ability
• Loss of language/communication (expressive language particularly affected)—regression from words/babbling to loss of purposeful speech
• Characteristic stereotyped hand movements (pathognomonic): midline hand stereotypies (hand wringing, hand clasping, hand mouthing, hand washing, tapping) occurring during wakefulness
• Loss of social engagement and development of autism-like features (though Rett is distinct from autism spectrum disorder)
• Truncal ataxia and gait disturbance—loss of coordinated movement, intention tremor
• Seizures (60-80% develop)—typically myoclonic, tonic-clonic, or focal; often refractory
• Breathing abnormalities (40-60%)—apnea during sleep, hyperventilation during waking hours, breath-holding, irregular breathing patterns

Stage III (Plateau/Pseudo-Stationary Stage; 2-10 years)

• Stabilization or slowing of regression
• Persistence of severe intellectual disability and physical disability
• Continued seizures and breathing abnormalities
• Improved eye contact and social responsiveness ("eye pointing")—paradoxical improvement in nonverbal communication
• Severe motor dysfunction—spasticity, rigidity, dystonia
• Development of scoliosis and contractures from immobility

Stage IV (Late Motor Deterioration Stage; >10 years)

• Prominent rigidity and dystonia
• Loss of autonomous ambulation—progression to wheelchair dependence
• Severe spasticity with extensor posturing
• Development of severe scoliosis (progressive, often requires surgical intervention)
• Growth deceleration and nutritional issues
• Increasing seizure frequency or late seizure development
• Loss of communication skills but often retained comprehension and awareness
• Potential prolonged survival into adulthood with appropriate care

Physical Examination Findings

• Distinctive hand stereotypies (midline, bilateral, symmetrical)
• Normal head circumference (relative macrocephaly in context of overall growth deceleration)
• Spasticity (lower extremities > upper extremities)
• Hyperreflexia and extensor plantar responses (Babinski sign)
• Scoliosis (60-80% develop, often severe)
• Contractures of lower extremities
• Dystonia and rigidity in later stages
• Ataxia and intention tremor
• Normal or near-normal fundoscopic exam (distinguishes from other storage disorders)
• Normal visual and auditory responses (preserved basic sensory function initially)

Clinical Diagnostic Criteria (Diagnostic and Statistical Manual, DSM-5; International Classification of Diseases)

• Apparently normal psychomotor development for at least 5 months (typically 6-18 months)
• Normal head circumference at birth
• Deceleration of head growth between ages 5-48 months
• Loss of purposeful hand skills between ages 6-30 months (most common between 8-12 months)
• Loss of social engagement in early stages
• Appearance of poorly coordinated or repetitive movements (stereotyped hand movements)
• Severe problems in expressive and receptive language development
• Severe psychomotor retardation (intellectual disability)

Genetic Testing

• MECP2 gene sequencing and deletion/duplication analysis: Gold standard for diagnosis; detects >99% of classic Rett mutations
• Panel testing: Consider sequencing CDKL5, PCDH19, FOXG1, and other atypical Rett-associated genes in cases with atypical features or negative MECP2 testing
• X-inactivation pattern analysis: Can be performed to predict severity but not routinely necessary for diagnosis

Electroencephalography (EEG)

• Abnormal background rhythms: Generalized slowing, disorganized background
• Abnormal paroxysmal activity: Epileptiform discharges, multifocal sharp waves, spike-and-wave complexes
• Pattern evolution: EEG abnormalities become more prominent with disease progression
• Not diagnostic but supportive; typical findings in later stages include increased paroxysmal activity and slowing

Neuroimaging (Brain MRI)

• Usually normal or nonspecific findings in early disease
• Progressive findings: Delayed myelination, cerebral and cerebellar atrophy (develops over time)
• Basal ganglia abnormalities in some cases (reduced volume, signal changes)
• White matter changes (nonspecific)
• Rule-out alternative diagnoses such as progressive storage disorders, leukodystrophies, or structural abnormalities
• Not required for diagnosis but helps exclude other etiologies

Laboratory Studies

• Comprehensive metabolic panel and liver function tests: Screen for metabolic causes and establish baseline before antiepileptic drug therapy
• Mitochondrial studies (serum and CSF lactate, pyruvate): May show mild elevation suggesting mitochondrial dysfunction, but nonspecific
• Blood smear and metabolic screening: Exclude lysosomal storage disorders and metabolic diseases
• Newborn screening results: Review to exclude detected metabolic disorders

Differential Diagnosis Exclusion

• Autism spectrum disorder: Rett differs by regression after period of normal development (autism evident by 12-24 months without clear regression)
• Cerebral palsy: No regression; static motor impairment
• Angelman syndrome: Different genetic etiology, different clinical pattern
• Fragile X syndrome: Different inheritance pattern, different clinical features, different genetic mutation
• Progressive storage disorders: Gradual onset without period of normal development, different biochemical markers
• Early infantile epileptic encephalopathy (CDKL5-related): Seizures onset earlier (<3 months), different trajectory

General Approach

Seizure Management (First-Line Therapy)

• Valproic acid (sodium valproate): Most commonly used first-line agent; broad-spectrum efficacy; starting dose 10-15 mg/kg/day divided twice daily, titrate to effect; effective in 60-70% of Rett seizures; monitor liver function and platelet count; use cautiously given risk of hepatotoxicity
• Levetiracetam (Keppra): Increasingly used first-line agent; broad spectrum; good tolerability profile; starting dose 10-20 mg/kg/day divided twice daily; fewer drug interactions than valproate; may cause behavioral changes
• Lamotrigine: Second-line agent; effective for myoclonic seizures; slow titration required to minimize rash risk; starting dose 0.3-1 mg/kg/day
• Topiramate: Alternative broad-spectrum agent; dose range 5-9 mg/kg/day; monitor for cognitive side effects
• Benzodiazepines: Acute seizure management (lorazepam, diazepam); long-term use (clonazepam, clobazam) for breakthrough seizures; risk of tolerance and dependence
• Combination therapy: Often necessary; many patients require 2-3 antiepileptic drugs for seizure control
• Vagal nerve stimulation: Consider for medically refractory seizures

Management of Breathing Abnormalities

• Structured behavioral approaches: Scheduled breathing exercises, environmental triggers identification
• Oxygen supplementation: During sleep if hypoxemia documented
• Non-invasive ventilation: BiPAP/CPAP for sleep-disordered breathing if indicated
• Monitor for aspiration given swallowing dysfunction risk

Spasticity and Movement Disorder Management

• Physical therapy and stretching: Regular ROM exercises crucial to prevent contractures; should be performed daily
• Baclofen: Initial dose 5-10 mg divided TID, titrate to 40-80 mg/day; GABA-B agonist; reduces spasticity; may cause sedation
• Botulinum toxin injections: Local administration to severely hypertonic muscles; effective for focal spasticity; requires repeat injections every 3 months
• Orthotic devices: Bracing to maintain alignment and prevent contractures
• Surgical intervention: Orthopedic surgery for severe contractures or scoliosis correction if needed; assess surgical candidacy carefully

Scoliosis Management

• Serial monitoring: Regular radiographic assessment; spine progresses in 60-80% of patients
• Physical therapy and bracing: Slow progression but cannot prevent
• Surgical fusion: Consider when curve >50 degrees, progressive despite bracing, or compromising respiratory function; assess perioperative risk carefully

Nutritional Support

• Assessment of swallowing function: Videofluoroscopic swallow study if aspiration risk suspected
• Oral feeding optimization: Modified diet consistency, positioning during feeds
• Tube feeding: Nasogastric (NG) or percutaneous endoscopic gastrostomy (PEG) tube for inadequate intake or aspiration risk; many Rett patients require supplemental/complete tube feeding
• Micronutrient supplementation: Calcium, vitamin D for bone health; general multivitamin
• Monitor growth parameters and nutritional status regularly

Behavioral and Communication Support

• Speech-language pathology: Augmentative/alternative communication (AAC) devices; communication boards; eye-gaze technology for nonverbal communication
• Occupational therapy: Adaptive equipment, activity modification
• Behavioral intervention: Address challenging behaviors; structured environment; consistent routines
• Psychosocial support for family: Genetic counseling, support groups, respite care resources

Cardiac Monitoring

• Baseline ECG and periodic cardiac assessment: Prolonged QT interval documented in some Rett patients; risk of sudden cardiac death
• Consider continuous cardiac monitoring in advanced stages

Bone Health

• DEXA scan: Assess for osteoporosis (common in Rett due to immobility, seizure medications)
• Vitamin D and calcium supplementation: Maintain adequate intake
• Weight-bearing activity: Encourage ambulation or supported standing

Emerging Therapies (Research/Investigational)

• IGF-1 (insulin-like growth factor-1): Limited evidence of benefit in clinical trials
• Gene therapy approaches: Experimental; targeting MECP2 restoration in clinical trials
• HDAC inhibitors and other molecular approaches: Under investigation

Early and Common Complications

• Seizures (60-80%)—often refractory to single-agent therapy; status epilepticus risk; SUDEP (sudden unexpected nocturnal death in epilepsy) risk
• Aspiration and swallowing dysfunction (progressive)—leading cause of morbidity/mortality in later stages; recurrent respiratory infections
• Respiratory infections (pneumonia)—due to aspiration, swallowing dysfunction, and impaired mobility; major contributor to morbidity
• Malnutrition and growth deceleration—from dysphagia, difficulty feeding, increased metabolic needs

Orthopedic Complications

• Scoliosis (60-80%)—severe, progressive; compromises respiratory function; can be life-threatening if not managed; often requires surgical intervention
• Hip dislocation—occurs in subset of patients; pain management, positioning optimization
• Contractures (progressive)—lower extremities predominantly; limit mobility and cause discomfort; prevent with stretching and positioning

Neurological Complications

• Progressive motor deterioration—loss of ambulation by teen years in many cases
• Dystonia and rigidity—progressive, painful; difficult to manage
• Autonomic dysfunction—temperature dysregulation, abnormal sweating
• Sleep disturbances—insomnia, irregular sleep-wake cycles; impact quality of life

Gastrointestinal Complications

• Gastroesophageal reflux disease (GERD)—common; increased aspiration risk; manage with medications (proton pump inhibitors) and positioning
• Constipation (significant)—due to immobility, medications, dysmotility; require bowel management program; stool softeners, osmotic laxatives
• Incontinence (fecal and urinary)

Cardiac Complications

• QT prolongation (documented in some cases)—risk of arrhythmias including torsades de pointes
• Sudden unexplained nocturnal death in epilepsy (SUDEP)—documented in Rett cohorts; unknown incidence but recognized complication

Life-Threatening Complications

• Status epilepticus—medical

The stem that gives it away

• A girl, normal until 6–18 months, then regression: loss of purposeful hand use and spoken language after a period of unambiguously normal milestones. Regression after normal development is the discriminator — autism spectrum disorder classically shows delay/deviance without loss of previously acquired hand skills.
• **Midline hand-wringing / hand-washing stereotypies**: bilateral, symmetric, present only in wakefulness and absent in sleep. This is the single most tested buzzword.
• Acquired microcephaly: head circumference is normal at birth, then decelerates between ~5 and 48 months. A stem describing congenital microcephaly is pointing elsewhere.

Best next step

• **Targeted MECP2 sequencing with deletion/duplication analysis** confirms clinically suspected classic Rett (diagnosis itself remains clinical, per the RettSearch consensus criteria). EEG and MRI support or exclude alternatives but do not make the diagnosis. When the phenotype is atypical or MECP2 is negative, ACMG supports broader genomic testing (multigene panel or exome/genome sequencing) as first-tier evaluation of global developmental delay/intellectual disability.

The association examiners test

• **X-linked dominant, essentially all *de novo***: recurrence risk for siblings is low but not zero because of maternal germline mosaicism — offer genetic counseling. Hemizygous males are typically lethal (neonatal encephalopathy); surviving males usually have mosaicism or a Klinefelter (47,XXY) karyotype.
• Prolonged QT: get a baseline ECG and avoid stacking QT-prolonging agents; this plus seizures underlies the sudden-death risk.

Common distractors

• Angelman syndrome (UBE3A, maternal 15q11-13): happy affect, inappropriate laughter, ataxic "puppet" gait, hand-flapping — no true loss of acquired hand skills, and no hand-wringing.
• CDKL5 disorder: refractory seizures beginning in the first months of life, before any normal developmental period.
• Fragile X: males, macroorchidism, no regression phase.
• Do not call this a lysosomal storage disease: fundoscopy, organomegaly, and coarse features are absent.

Therapeutics

• Trofinetide, an IGF-1–derived peptide, is FDA-approved for Rett syndrome; care otherwise remains supportive and multidisciplinary.